About
Karen Wagner is a Managing Partner at Ysios Capital, where she works on therapeutic investments and helps identify and evaluate opportunities. She joined Ysios in 2008 after more than a decade in biotech and pharma business development, having begun her career as a management consultant in McKinsey & Company's healthcare practice and later served as Director of Business Development at Ingenium Pharmaceuticals. She previously worked at Glycart Biotechnology and, following its acquisition by F. Hoffmann-La Roche, led business development and alliance management at Roche; she holds a Master's in Molecular Biology and a PhD in Cell Biology from the University of Konstanz.
Invests in
Biotech
Experience
- Ysios CapitalGeneral Partnercurrent2007 — present
- Independent ConsultantConsultant Business Development2007 — 2014
- F. Hoffmann-La Roche LtdGlobal Alliance Director2005 — 2007
- GlycArt Biotechnology AGVP Licensing2004 — 2005
- Ingenium Pharmaceuticals AGDirector Business Development2001 — 2004
- McKinsey & CompanyConsultant1998 — 2001
Education
- University of KonstanzPhD, Molecular and Cell Biology1989 — 1995
Skills & more
From Karen's professional profile.
Same school
Also attended University of Konstanz13
+ 7 more
Shared employers
Also worked at F. Hoffmann-La Roche Ltd75
+ 69 more
Also worked at McKinsey & Company1,128
.jpg)
+ 1,122 more
Investments
Board seats
AELIX TherapeuticsCardozCytoki PharmaGalectoKala PharmaceuticalsMinoryx TherapeuticsSparingVisionSynendosVivet TherapeuticsXeltis
Per the firm's website.
Colleagues at Ysios Capital
Network2
Investors connected to Karen in public investor directories — a warm-intro map.